LT2961410T - Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus - Google Patents

Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus

Info

Publication number
LT2961410T
LT2961410T LTEP14710739.5T LT14710739T LT2961410T LT 2961410 T LT2961410 T LT 2961410T LT 14710739 T LT14710739 T LT 14710739T LT 2961410 T LT2961410 T LT 2961410T
Authority
LT
Lithuania
Prior art keywords
treatment
related disorders
pyrazolopyrimidine derivatives
pi3k related
pi3k
Prior art date
Application number
LTEP14710739.5T
Other languages
English (en)
Inventor
Yun-Long Li
Wenqing Yao
Andrew P. Combs
Eddy W. Yue
Song MEI
Wenyu Zhu
Joseph Glenn
Maduskuie, Jr.
Richard B. Sparks
Brent Douty
Chunhong He
Original Assignee
Incyte Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corporation filed Critical Incyte Holdings Corporation
Publication of LT2961410T publication Critical patent/LT2961410T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP14710739.5T 2013-03-01 2014-02-28 Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus LT2961410T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01
PCT/US2014/019372 WO2014134426A1 (en) 2013-03-01 2014-02-28 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS

Publications (1)

Publication Number Publication Date
LT2961410T true LT2961410T (lt) 2020-02-10

Family

ID=50288319

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14710739.5T LT2961410T (lt) 2013-03-01 2014-02-28 Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus

Country Status (32)

Country Link
US (5) US9932341B2 (lt)
EP (3) EP3632442B1 (lt)
JP (4) JP6545106B2 (lt)
KR (3) KR102298150B1 (lt)
CN (2) CN105120871B (lt)
AR (1) AR094964A1 (lt)
AU (4) AU2014223257B2 (lt)
BR (1) BR112015020941A2 (lt)
CA (1) CA2901993C (lt)
CL (1) CL2015002442A1 (lt)
CR (1) CR20150472A (lt)
CY (1) CY1122712T1 (lt)
DK (1) DK2961410T3 (lt)
EA (2) EA202192151A1 (lt)
ES (2) ES2945212T3 (lt)
HK (1) HK1221398A1 (lt)
HR (1) HRP20200263T1 (lt)
HU (1) HUE047719T2 (lt)
IL (6) IL311666A (lt)
LT (1) LT2961410T (lt)
MX (2) MX367713B (lt)
MY (1) MY177875A (lt)
PE (1) PE20151996A1 (lt)
PH (2) PH12015501920A1 (lt)
PL (1) PL2961410T3 (lt)
PT (1) PT2961410T (lt)
RS (1) RS59958B1 (lt)
SG (3) SG11201506654UA (lt)
SI (1) SI2961410T1 (lt)
TW (5) TW202214254A (lt)
UA (1) UA119641C2 (lt)
WO (1) WO2014134426A1 (lt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TW202214254A (zh) * 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
PL3129021T3 (pl) 2014-04-08 2021-05-31 Incyte Corporation Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI748941B (zh) * 2015-02-27 2021-12-11 美商英塞特公司 Pi3k抑制劑之鹽及製備方法
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
US9822122B2 (en) 2016-03-31 2017-11-21 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
AU2018328569B2 (en) * 2017-09-08 2023-07-27 Beigene, Ltd. Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102574564B1 (ko) 2018-01-10 2023-09-04 이도르시아 파마슈티컬스 리미티드 혈관염 및 염증성 질환을 치료하기 위한 c5a 수용체 조절제로서의 2,4,6,7-테트라히드로-피라졸로[4,3-d]피리미딘-5-온 유도체 및 관련 화합물
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
MA52761A (fr) 2018-06-01 2021-04-14 Incyte Corp Schéma posologique destiné au traitement de troubles liés à la pi3k
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
JP2021535182A (ja) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation ホスホイノシチド3−キナーゼ(pi3k)阻害剤の結晶形態
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
TW202329976A (zh) 2021-12-16 2023-08-01 美商英塞特公司 P13K—δ抑制劑之局部調配物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
US20090156602A1 (en) 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン, エルエルシー 複素環キナーゼ阻害剤
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
JP2013503183A (ja) 2009-08-28 2013-01-31 武田薬品工業株式会社 mTOR阻害剤として使用するヘキサヒドロオキサジノプテリン化合物
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW202214254A (zh) * 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI748941B (zh) * 2015-02-27 2021-12-11 美商英塞特公司 Pi3k抑制劑之鹽及製備方法
MA52761A (fr) * 2018-06-01 2021-04-14 Incyte Corp Schéma posologique destiné au traitement de troubles liés à la pi3k
WO2020102150A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Also Published As

Publication number Publication date
CN105120871B (zh) 2018-08-10
AU2020210278B2 (en) 2022-05-26
EP4233869A2 (en) 2023-08-30
KR20150135327A (ko) 2015-12-02
PE20151996A1 (es) 2016-01-13
PT2961410T (pt) 2020-03-02
IL274771A (en) 2020-07-30
IL301180A (en) 2023-05-01
KR20230145517A (ko) 2023-10-17
PH12015501920B1 (en) 2016-01-18
WO2014134426A1 (en) 2014-09-04
IL283943A (en) 2021-07-29
KR102454308B1 (ko) 2022-10-14
IL240784B (en) 2020-06-30
TWI841376B (zh) 2024-05-01
MX367713B (es) 2019-09-03
CL2015002442A1 (es) 2016-02-05
CY1122712T1 (el) 2021-03-12
AR094964A1 (es) 2015-09-09
HUE047719T2 (hu) 2020-05-28
SI2961410T1 (sl) 2020-03-31
ES2774436T3 (es) 2020-07-21
SG11201506654UA (en) 2015-09-29
HK1221398A1 (zh) 2017-06-02
JP6776399B2 (ja) 2020-10-28
BR112015020941A2 (pt) 2017-07-18
EP2961410A1 (en) 2016-01-06
TW201444846A (zh) 2014-12-01
IL283943B1 (en) 2023-04-01
JP7189185B2 (ja) 2022-12-13
TWI687220B (zh) 2020-03-11
SG10201912275YA (en) 2020-04-29
EP4233869A3 (en) 2023-11-01
EP2961410B1 (en) 2019-12-11
CA2901993C (en) 2023-03-07
JP7556010B2 (ja) 2024-09-25
CN105120871A (zh) 2015-12-02
TW202019428A (zh) 2020-06-01
HRP20200263T1 (hr) 2020-05-29
DK2961410T3 (da) 2020-02-17
KR20220143146A (ko) 2022-10-24
AU2018264053B2 (en) 2020-08-20
TW201929860A (zh) 2019-08-01
JP2021020914A (ja) 2021-02-18
CA2901993A1 (en) 2014-09-04
RS59958B1 (sr) 2020-03-31
UA119641C2 (uk) 2019-07-25
TWI657090B (zh) 2019-04-21
TW202333734A (zh) 2023-09-01
AU2020210278A1 (en) 2020-08-20
IL311666A (en) 2024-05-01
US20220106318A1 (en) 2022-04-07
IL267853B (en) 2020-03-31
IL283943B2 (en) 2023-08-01
PH12019501321B1 (en) 2020-10-12
US20140249132A1 (en) 2014-09-04
CR20150472A (es) 2016-01-04
JP2019142941A (ja) 2019-08-29
US20220119393A1 (en) 2022-04-21
MY177875A (en) 2020-09-24
US20190040067A1 (en) 2019-02-07
ES2945212T3 (es) 2023-06-29
MX2015011273A (es) 2015-12-03
IL267853A (en) 2019-09-26
AU2014223257A1 (en) 2015-09-24
JP2023036609A (ja) 2023-03-14
TW202214254A (zh) 2022-04-16
EA201591612A1 (ru) 2016-05-31
KR102298150B1 (ko) 2021-09-07
IL240784A0 (en) 2015-10-29
EP3632442B1 (en) 2023-04-05
KR102586858B1 (ko) 2023-10-11
CN109010343A (zh) 2018-12-18
EA202192151A1 (ru) 2021-12-31
KR20210110409A (ko) 2021-09-07
US20210332059A1 (en) 2021-10-28
AU2018264053A1 (en) 2018-12-06
EP3632442A1 (en) 2020-04-08
JP2016510035A (ja) 2016-04-04
TWI736135B (zh) 2021-08-11
PH12015501920A1 (en) 2016-01-18
PL2961410T3 (pl) 2020-05-18
US9932341B2 (en) 2018-04-03
JP6545106B2 (ja) 2019-07-17
MX2019010422A (es) 2019-10-15
AU2014223257B2 (en) 2018-11-29
AU2022218495B2 (en) 2024-10-03
AU2022218495A1 (en) 2022-09-08
PH12019501321A1 (en) 2020-10-12
SG10201707130UA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
IL243976B (en) kdm1a inhibitors for disease treatment
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
PL3007694T3 (pl) Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
HK1223547A1 (zh) 癌症治療方法
HK1221166A1 (zh) 炎症性病症的治療
EP3089984A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
ZA201508530B (en) Pyrazolopyridine derivatives for use in the treatment of bladder cancer
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS